MCID: CYS014
MIFTS: 51

Cystadenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Cystadenocarcinoma

MalaCards integrated aliases for Cystadenocarcinoma:

Name: Cystadenocarcinoma 12 51 41 14 69
Cystadenocarcinoma Nos 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3111
MeSH 41 D003536
NCIt 46 C2971
SNOMED-CT 64 189681005 21008007
UMLS 69 C0010631

Summaries for Cystadenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, in which cystic accumulations of retained secretions are formed.

MalaCards based summary : Cystadenocarcinoma, also known as cystadenocarcinoma nos, is related to mucinous cystadenocarcinoma and bile duct cystadenocarcinoma. An important gene associated with Cystadenocarcinoma is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways are Pathways in cancer and MicroRNAs in cancer. The drugs Bevacizumab and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include ovary, pancreas and liver, and related phenotypes are Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance and cellular

Related Diseases for Cystadenocarcinoma

Diseases related to Cystadenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 311)
# Related Disease Score Top Affiliating Genes
1 mucinous cystadenocarcinoma 33.0 KRT7 MUC1 MUC2 PTPRC SLCO4A1 VIM
2 bile duct cystadenocarcinoma 32.9 CEACAM5 KRT7 MUC1 MUC2
3 papillary serous adenocarcinoma 32.7 KRT7 PGR TP53
4 ovarian serous cystadenocarcinoma 32.7 AKT1 ESR2 PGR VEGFA ZNF217
5 serous cystadenocarcinoma 31.7 AKT1 ALPP CDKN1A ESR2 PGR TP53
6 cystadenoma 30.9 KRT7 MUC1 MUC2 PGR
7 giant cell tumor 30.6 MUC1 PTPRC VIM
8 cystic teratoma 30.5 KRT7 MUC2 TP53
9 pseudomyxoma peritonei 30.4 KRT7 MUC1 MUC2 TP53
10 polymorphous low-grade adenocarcinoma 30.0 CEACAM3 MUC1 VIM
11 endosalpingiosis 30.0 KRT7 MUC1 PGR
12 dermoid cyst 30.0 KRT7 MUC1 PGR VIM
13 mucinous adenocarcinoma 29.9 KRT7 MUC1 MUC2 TP53
14 leiomyosarcoma 29.9 PGR TP53 VIM
15 appendix cancer 29.9 KRT7 MUC1 MUC2
16 adenosquamous carcinoma 29.8 KRT7 MUC1 TP53
17 small cell carcinoma 29.8 KRT7 PTPRC TP53
18 intrahepatic cholangiocarcinoma 29.5 KRT7 MUC1 MUC2 TP53
19 angiosarcoma 29.5 MUC1 TP53 VEGFA VIM
20 adenocarcinoma 29.2 AKT1 CDKN1A MUC1 TP53 VEGFA
21 pancreatic ductal carcinoma 29.1 KRT7 MUC1 MUC2 TP53 VEGFA
22 renal cell carcinoma, nonpapillary 29.0 AKT1 KRT7 MUC1 VEGFA VIM
23 endometriosis 29.0 ESR2 MUC16 PGR VEGFA
24 papillary adenocarcinoma 28.9 CEACAM5 KRT7 MUC1 MUC2 PGR VIM
25 cholangiocarcinoma 28.9 CEACAM3 CEACAM5 KRT7 MUC1 MUC2
26 squamous cell carcinoma 28.0 CDKN1A CEACAM5 KRT7 MUC1 TP53 VEGFA
27 hepatocellular carcinoma 27.5 AKT1 CDKN1A CEACAM5 KRT7 TP53 VEGFA
28 ovarian cancer 1 27.2 AKT1 CEACAM5 KRT7 MUC1 MUC16 PGR
29 pancreatic cancer 27.1 AKT1 CDKN1A CEACAM3 CEACAM5 MUC1 MUC2
30 ovarian cancer 26.1 AKT1 ALPP CDKN1A CEACAM3 ESR2 KRT7
31 papillary cystadenocarcinoma 12.3
32 ovarian mucinous cystadenocarcinoma 12.1
33 ovarian cystadenocarcinoma 12.1
34 pancreatic serous cystadenocarcinoma 12.1
35 pancreatic cystadenocarcinoma 12.0
36 acinar cell cystadenocarcinoma 12.0
37 mucinous cystadenocarcinoma of the pancreas 12.0
38 appendix mucinous cystadenocarcinoma 11.9
39 breast mucinous cystadenocarcinoma 11.8
40 pancreatic non-invasive mucinous cystadenocarcinoma 11.8
41 ovarian clear cell cystadenocarcinoma 11.8
42 pancreatic colloid cystadenocarcinoma 11.8
43 pancreatic invasive mucinous cystadenocarcinoma 11.8
44 multilocular clear cell renal cell carcinoma 11.4
45 appendix adenocarcinoma 11.0
46 multilocular cystic renal neoplasm of low malignant potential 10.8
47 lymphangiomatosis 10.6 PGR VIM
48 primary hepatic neuroendocrine carcinoma 10.6 ALPP VIM
49 primitive neuroectodermal tumor of the cervix uteri 10.5 PTPRC VIM
50 endometrium carcinoma in situ 10.5 PGR TP53

Graphical network of the top 20 diseases related to Cystadenocarcinoma:



Diseases related to Cystadenocarcinoma

Symptoms & Phenotypes for Cystadenocarcinoma

GenomeRNAi Phenotypes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.02 ALPP MUC1 PTPRC VEGFA VIM

MGI Mouse Phenotypes related to Cystadenocarcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.96 KRT7 MUC2 PGR PTPRC TP53 VEGFA
2 muscle MP:0005369 9.7 PGR TP53 VEGFA VIM AKT1 CDKN1A
3 neoplasm MP:0002006 9.56 MUC2 PGR PTPRC TP53 VEGFA AKT1
4 respiratory system MP:0005388 9.17 PTPRC TP53 VEGFA VIM AKT1 CDKN1A

Drugs & Therapeutics for Cystadenocarcinoma

Drugs for Cystadenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
2
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
3
Cetuximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 205923-56-4 56842117 2333
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
6
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
7
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
8
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
9
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
10
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
11
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
12
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
13
Topotecan Approved, Investigational Phase 2, Phase 3, Phase 1 119413-54-6, 123948-87-8 60700
14
Everolimus Approved Phase 2, Phase 3,Phase 1 159351-69-6 6442177
15
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
16
Sirolimus Approved, Investigational Phase 2, Phase 3,Phase 1 53123-88-9 46835353 6436030 5284616
17
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
18
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
19
Tamoxifen Approved Phase 2, Phase 3 10540-29-1 2733526
20
Trametinib Approved Phase 2, Phase 3,Phase 1 871700-17-3 11707110
21
Metformin Approved Phase 2, Phase 3,Phase 1 657-24-9 4091 14219
22
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
23
Olaparib Approved Phase 2, Phase 3,Phase 1 763113-22-0 23725625
24
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
25
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
26
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
27
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1 56-86-0 33032
28
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
29
Camptothecin Experimental Phase 3,Phase 2,Phase 1 7689-03-4
30
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
31
Docetaxel Approved May 1996, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124 9877265
32
Cediranib Investigational Phase 2, Phase 3,Phase 1 288383-20-0 9933475
33
Maleic acid Experimental Phase 2, Phase 3,Phase 1 110-16-7 444266
34 Alkylating Agents Phase 3,Phase 2,Phase 1
35 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
36 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
37 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
38 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
39 Antidotes Phase 3,Phase 2,Phase 1
40 Antimetabolites Phase 3,Phase 2,Phase 1
41 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
43 Calcium, Dietary Phase 3,Phase 2,Phase 1
44 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
45 Micronutrients Phase 3,Phase 2,Phase 1,Early Phase 1
46 Mitomycins Phase 3
47 Nucleic Acid Synthesis Inhibitors Phase 3
48 Protective Agents Phase 3,Phase 2,Phase 1
49 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
50 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 176)

# Name Status NCT ID Phase Drugs
1 Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer Unknown status NCT01167725 Phase 3 FOLFIRI regimen;FOLFOX regimen;capecitabine;fluorouracil;irinotecan hydrochloride;leucovorin calcium;mitomycin C;oxaliplatin
2 Radiation Therapy Plus Chemotherapy Before Surgery With or Without Chemotherapy After Surgery in Treating Patients With Rectal Cancer Unknown status NCT00002896 Phase 3 chemotherapy;fluorouracil;leucovorin calcium
3 Edrecolomab in Treating Patients With Stage II Colon Cancer Completed NCT00002968 Phase 3
4 High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer Completed NCT00004150 Phase 3 fluorouracil;leucovorin calcium
5 Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00005036 Phase 3 irinotecan hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
6 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
7 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3 cisplatin;paclitaxel
8 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Newly Diagnosed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
9 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3 cisplatin;paclitaxel
10 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3 cisplatin;paclitaxel
11 Carboplatin Plus Paclitaxel With or Without Continued Low-Dose Paclitaxel in Treating Patients With Early-Stage Ovarian Cancer Completed NCT00003644 Phase 3 carboplatin;paclitaxel
12 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
13 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
14 Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol Recruiting NCT02501954 Phase 3 Cisplatin;Carboplatin;Paclitaxel
15 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3 Letrozole;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Tamoxifen Citrate;Topotecan Hydrochloride;Trametinib
16 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3 Carboplatin;Metformin Hydrochloride;Paclitaxel
17 Short Course Vaginal Cuff Brachytherapy in Treating Patients With Stage I-II Endometrial Cancer Recruiting NCT03422198 Phase 3
18 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
19 Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00951496 Phase 3 Carboplatin;Carboplatin;Cisplatin;Paclitaxel;Paclitaxel
20 Treatment Plan for an Individual Patient With Recurrent Uterine Papillary Serous Carcinoma (UPSC) With PIK3CA Gene Mutation Active, not recruiting NCT03285802 Phase 2, Phase 3 Letrozole;Everolimus
21 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3 Capecitabine;Carboplatin;Oxaliplatin;Paclitaxel
22 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
23 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
24 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
25 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
26 Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Active, not recruiting NCT00942357 Phase 3 Carboplatin;Cisplatin;Paclitaxel
27 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3 Carboplatin;Paclitaxel
28 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
29 Comparison of Adjuvant Chemotherapy Regimens in Treating Patients With Stage II or Stage III Rectal Cancer Who Are Receiving Radiation Therapy and Fluorouracil Before or After Surgery Terminated NCT00068692 Phase 3 capecitabine;fluorouracil;leucovorin calcium;irinotecan hydrochloride;oxaliplatin
30 Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer Terminated NCT00003880 Phase 2, Phase 3 carboplatin;paclitaxel
31 Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Persistent Ovarian Epithelial Cancer Terminated NCT00002819 Phase 3 carboplatin;cyclophosphamide;mitoxantrone hydrochloride;paclitaxel
32 Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy Withdrawn NCT01492920 Phase 3
33 Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer Unknown status NCT02112552 Phase 2 Paclitaxel;Carboplatin
34 Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer Unknown status NCT00017303 Phase 2 carboplatin;oglufanide disodium;paclitaxel
35 Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer Completed NCT01196429 Phase 2 Carboplatin;Docetaxel;Paclitaxel;Temsirolimus
36 Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy Completed NCT00004547 Phase 2 Postoperative dwell with paclitaxel and 5-FU
37 Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin Completed NCT00993616 Phase 2 belinostat;carboplatin
38 A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT00939809 Phase 2
39 Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy Completed NCT00466960 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation
40 Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma Completed NCT00059787 Phase 2 paclitaxel;carboplatin;erlotinib
41 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2 Paclitaxel;Dexamethasone;Cimetidine;Diphenhydramine
42 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2 Imatinib Mesylate;Paclitaxel
43 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
44 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01225887 Phase 2 Nintedanib
45 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01642082 Phase 2
46 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00888173 Phase 2 Brivanib Alaninate
47 Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer Completed NCT00100841 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
48 S0009 Combination Chemo and Surgery in Stage III or Stage IV Ovarian Cancer Completed NCT00008138 Phase 2 carboplatin;paclitaxel
49 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00003944 Phase 2 carboplatin;cyclophosphamide;paclitaxel;topotecan hydrochloride
50 Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Completed NCT00217529 Phase 1, Phase 2 carboplatin;docetaxel;erlotinib hydrochloride

Search NIH Clinical Center for Cystadenocarcinoma

Cochrane evidence based reviews: cystadenocarcinoma

Genetic Tests for Cystadenocarcinoma

Anatomical Context for Cystadenocarcinoma

MalaCards organs/tissues related to Cystadenocarcinoma:

38
Ovary, Pancreas, Liver, Colon, Appendix, Salivary Gland, Bone

Publications for Cystadenocarcinoma

Articles related to Cystadenocarcinoma:

(show top 50) (show all 685)
# Title Authors Year
1
Expression of Yes-associated proteinA 1 and its clinical significance in ovarian serous cystadenocarcinoma. ( 28339095 )
2017
2
Acinar Cell Cystadenocarcinoma of the Pancreas. ( 29033770 )
2017
3
Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report. ( 28449606 )
2017
4
Low-grade Cribriform Cystadenocarcinoma: A Review of the Literature and Case Report. ( 28507867 )
2017
5
Pancreatic pseudocyst or mucinous cystadenocarcinoma of pancreas? A diagnostic dilemma. ( 28396777 )
2017
6
Papillary cystadenocarcinoma of the sublingual gland. ( 29124004 )
2017
7
Clinicopathological features and post-resection outcomes of biliary cystadenoma and cystadenocarcinoma of the liver. ( 28989996 )
2017
8
Serous cystadenocarcinoma of the spleen. ( 28491168 )
2017
9
The long-term survival in primary retroperitoneal mucinous cystadenocarcinoma: a case report. ( 29177806 )
2017
10
(18)F-FDG PET/CT Imaging of Pulmonary Mucinous Cystadenocarcinoma with Signet Ring Cells. ( 28878858 )
2017
11
High Grade Serous Cystadenocarcinoma of Testis-Case Report of a Rare Ovarian Epithelial Type Tumour. ( 28764180 )
2017
12
Krukenberg carcinoma metastasized from stomach resembling mucinous cystadenocarcinoma of the ovary. ( 28976119 )
2017
13
Biliary Cystadenoma and Cystadenocarcinoma of the Gallbladder: A Clinical Review. ( 28637540 )
2017
14
Low-grade intraductal carcinoma (low-grade cribriform cystadenocarcinoma) with tumor-associated lymphoid proliferation of parotid gland. ( 28551385 )
2017
15
Mucinous cystadenocarcinoma of the breast: the challenge of diagnosing a rare entity. ( 29081926 )
2017
16
Contrast enhanced ultrasound features of hepatic cystadenoma and hepatic cystadenocarcinoma. ( 27887203 )
2017
17
Mucinous cystadenocarcinoma of ovary with metastasis in 14-year-old girl. ( 28344967 )
2017
18
Pulmonary Mucinous Cystadenocarcinoma Presenting as Extensive Multifocal Cystic Lesions. ( 28199793 )
2017
19
Primary seromucinous cystadenocarcinoma of the mesentery. ( 28240468 )
2016
20
Recto-vaginal septum cystadenocarcinoma: a case report and review of the literature. ( 27142415 )
2016
21
Radiologic Findings of Primary Mucinous Cystadenocarcinoma of the Breast: A Report of Two Cases and a Literature Review. ( 27721884 )
2016
22
Mucinous cystadenocarcinoma of the pancreas with anaplastic carcinoma: A case report and review of the literature. ( 27073646 )
2016
23
Primary retroperitoneal mucinous cystadenocarcinoma (PRMCa): a systematic review of the literature and meta-analysis. ( 26681306 )
2016
24
Retraction note: Metastatic ovarian papillary cystadenocarcinoma to the small intestine serous surface: report of a case of high-grade histopathologic malignancy. ( 27814773 )
2016
25
Serous Cystadenocarcinoma of the Pancreas: Clinical Features and Management of a Rare Tumor. ( 26998825 )
2016
26
Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm. ( 27367953 )
2016
27
DNA methylation-regulated microRNA pathways in ovarian serous cystadenocarcinoma: A meta-analysis. ( 27746113 )
2016
28
OK-432 injection therapy for cystadenocarcinoma of the parotid gland: A case report. ( 27140021 )
2016
29
Clinicopathological characteristics, treatment, and survival outcomes of cystadenocarcinoma of the salivary gland: a population-based study. ( 27822061 )
2016
30
Low-grade cribriform cystadenocarcinoma arising from a minor salivary gland: a case report. ( 27021553 )
2016
31
Cystic Epithelial Tumors of the Prostate: One Case Supporting a Continuous Spectrum From Cystadenoma to Cystadenocarcinoma With Ductal Features. ( 27631516 )
2016
32
Single nucleotide polymorphisms in glutathione S-transferase P1 and M1 genes and overall survival of patients with ovarian serous cystadenocarcinoma treated with chemotherapy. ( 27073511 )
2016
33
Pancreatic mucinous cystadenocarcinoma: Epidemiology and outcomes. ( 27638187 )
2016
34
Epididymal papillary cystadenocarcinoma metastasising to the testis in a patient with infertility managed with Onco-microTeSE. ( 27887012 )
2016
35
Serous Cystadenocarcinoma Arising in Presumed Vitelline Duct Remnant: A Case Report and Implications in the Management of Cancer of Unknown Primary. ( 27999702 )
2016
36
Cytomorphological features of papillary cystadenocarcinoma of parotid gland: A case report with review of literature. ( 27298629 )
2016
37
Mature Cystic Teratoma with Co-existent Mucinous Cystadenocarcinoma in the same Ovary-A Diagnostic Dilemma. ( 28208869 )
2016
38
Primary retroperitoneal mucinous cystadenocarcinoma in a male patient. ( 27166050 )
2016
39
Mucinous Cystadenocarcinoma in a Horse Shoe Kidney Masquerading as Giant Hydronephrosis - A Case Report: Diagnostic Challenges, Lessons Learnt and Review of Literature. ( 28050435 )
2016
40
Estimation of Prognostic Marker Genes by Public Microarray Data in Patients with Ovarian Serous Cystadenocarcinoma. ( 27189279 )
2016
41
Papillary Cystadenocarcinoma of the Parotid Gland: A Rare Case Report. ( 27504297 )
2016
42
A Rare biliary cystic tumors: a case series of biliary cystadenomas and cystadenocarcinoma. ( 27049501 )
2016
43
Degenerative hepatic hemangioma mimicking biliary cystadenocarcinoma. ( 26896817 )
2016
44
A Five-Gene Expression Signature Predicts Clinical Outcome of Ovarian Serous Cystadenocarcinoma. ( 27478834 )
2016
45
Cytomorphological findings and histological correlation of papillary cystadenocarcinoma of the parotid: Not always a low-grade tumor. ( 27510680 )
2016
46
Vaginal fold prolapse in a dog with pyometra and ovarian papillary cystadenocarcinoma. ( 27003024 )
2016
47
Giant mucinous cystadenocarcinoma of ovary: A case report and review of literature. ( 27134482 )
2016
48
Cytology of low-grade cribriform cystadenocarcinoma in salivary glands: Cytological and immunohistochemical distinctions from other salivary gland neoplasms. ( 26875597 )
2016
49
A giant mucinous cystadenocarcinoma of the appendix: a case report and review of the literature. ( 26945579 )
2016
50
Synchronous resection of pancreatic serous cystadenocarcinoma and liver metastasis: First reported case and review of literature. ( 26463518 )
2015

Variations for Cystadenocarcinoma

Expression for Cystadenocarcinoma

Search GEO for disease gene expression data for Cystadenocarcinoma.

Pathways for Cystadenocarcinoma

Pathways related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1 12.68 AKT1 CDKN1A ESR2 TP53 VEGFA
2 12.38 CDKN1A TP53 VEGFA VIM
3
Show member pathways
12.34 AKT1 CDKN1A TP53 VEGFA
4
Show member pathways
12.3 AKT1 CDKN1A ESR2 MUC2 PGR TP53
5
Show member pathways
12.18 AKT1 CDKN1A ESR2 TP53 VEGFA
6 12.1 AKT1 CDKN1A TP53 VIM
7 12.09 AKT1 CDKN1A TP53 VEGFA
8 11.92 AKT1 CDKN1A TP53 VEGFA
9
Show member pathways
11.81 AKT1 CDKN1A TP53 VEGFA
10 11.77 AKT1 CDKN1A VEGFA
11 11.73 AKT1 CDKN1A TP53
12 11.66 AKT1 CDKN1A TP53
13 11.59 AKT1 CDKN1A VIM
14 11.58 CDKN1A TP53 VEGFA
15 11.56 AKT1 CDKN1A TP53
16 11.4 AKT1 CDKN1A VEGFA
18 11.21 AKT1 CDKN1A TP53
19 11.16 AKT1 CDKN1A MUC1 TP53 VEGFA VIM
20 10.96 AKT1 CDKN1A TP53 VEGFA
21 10.66 CDKN1A TP53
22
Show member pathways
10.41 CDKN1A TP53

GO Terms for Cystadenocarcinoma

Cellular components related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC1 MUC16 MUC2

Biological processes related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.77 AKT1 CDKN1A CEACAM5 TP53 VEGFA
2 negative regulation of gene expression GO:0010629 9.62 AKT1 CDKN1A PGR VEGFA
3 positive regulation of leukocyte migration GO:0002687 9.43 TP53 VEGFA
4 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.43 CDKN1A MUC1 TP53
5 replicative senescence GO:0090399 9.4 CDKN1A TP53
6 O-glycan processing GO:0016266 9.33 MUC1 MUC16 MUC2
7 signal transduction by p53 class mediator GO:0072331 8.96 CDKN1A TP53
8 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 CDKN1A MUC1 TP53

Molecular functions related to Cystadenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 AKT1 CEACAM5 ESR2 PGR TP53 VEGFA

Sources for Cystadenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....